ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$18.75 USD
-0.39 (-2.04%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $18.76 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum B VGM
Acadia Pharmaceuticals (ACAD) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$27.45 | $39.00 | $13.00 | 43.42% |
Price Target
Based on short-term price targets offered by 20 analysts, the average price target for Acadia Pharmaceuticals comes to $27.45. The forecasts range from a low of $13.00 to a high of $39.00. The average price target represents an increase of 43.42% from the last closing price of $19.14.
Analyst Price Targets (20)
Broker Rating
Acadia Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.70 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 20 brokerage firms. The current ABR compares to an ABR of 1.70 a month ago based on 20 recommendations.
Of the 20 recommendations deriving the current ABR, 13 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 65% and 10% of all recommendations. A month ago, Strong Buy made up 65%, while Buy represented 10%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 13 | 13 | 13 | 12 | 12 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 4 | 4 | 4 | 4 | 5 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 1.70 | 1.70 | 1.70 | 1.74 | 1.80 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/24/2024 | Cantor Fitzgerald & Co | Charles C Duncan | Strong Buy | Strong Buy |
6/30/2024 | Goldman Sachs | Salveen Richter | Strong Sell | Strong Sell |
6/27/2024 | BMO Capital Markets | Evan Seigerman | Not Available | Strong Buy |
6/25/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
5/8/2024 | Not Identified | Not Identified | Hold | Hold |
5/8/2024 | SVB Securities | Marc Goodman | Strong Buy | Strong Buy |
4/29/2024 | UBS | Ashwani Verma | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Ritu S Baral | Strong Buy | Strong Buy |
3/12/2024 | JMP Securities | Jason N Butler | Strong Buy | Strong Buy |
3/12/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/12/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
3/12/2024 | Robert W. Baird & Co. | Joel L Beatty | Strong Buy | Strong Buy |
3/12/2024 | Canaccord Genuity | Sumant Kulkarni | Strong Buy | Strong Buy |
3/12/2024 | Not Identified | Not Identified | Hold | Hold |
3/12/2024 | Needham & Company | Ami Fadia | Moderate Buy | Moderate Buy |
3/12/2024 | Mizuho SecuritiesUSA | Uy D Ear | Strong Buy | Hold |
2/27/2024 | Guggenheim Securities | Yatin Suneja | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.70 |
ABR (Last week) | 1.70 |
# of Recs in ABR | 20 |
Average Target Price | $27.45 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 252 |
Current Quarter EPS Est: | 0.16 |